Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions

References

• Becker’s Hospital Review. Why many health systems are capitalizing on the growing home infusion therapy trend [Internet]. 2020; [cited 2021 Mar 16]. Available from: https://www.beckershospitalreview.com/pharmacy/why-many-health-systems-are-capitalizing-on-the-growing-home-infusion-therapy-trend.html
   Google Scholar
• Drapier S, Eusebio A, Degos B, et al. Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263(6):1111–1119.
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism Relat Disord. 2016;23:17–22.
   PubMed Web of Science ®Google Scholar
• García Ruiz PJ, Ignacio ÁS, Pensado BA, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130–1136.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–759.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151–157.
   PubMed Web of Science ®Google Scholar
• Mecklenburg RS, Benson EA, Benson JW, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA. 1984;252(23):3265–3269.
   PubMed Web of Science ®Google Scholar
• Olivola E, Fasano A, Varanese S, et al. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019;40(9):1917–1923.
   PubMed Web of Science ®Google Scholar
• Pickup JC, Yemane N, Brackenridge A, et al. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Therap. 2014;16(3):143–149.
   Web of Science ®Google Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709–716.
   PubMed Web of Science ®Google Scholar
• Ross P, Gray AR, Milburn J, et al. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Acta Diabetol. 2016;53(6):991–998.
   PubMed Web of Science ®Google Scholar
• Taleb N, Messier V, Ott-Braschi S, et al. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: results of an online survey. Diabetes Res Clin Pract. 2018;144:42–50.
   PubMed Web of Science ®Google Scholar
• van Faassen I, Razenberg PPA, Simoons-Smit AM, et al. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care. 1989;12(2):153–156.
   PubMed Web of Science ®Google Scholar
• Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: a retrospective long-term follow-up study. Parkinsonism Relat Disord. 2017;45:33–38. Available from:
   PubMed Web of Science ®Google Scholar
• Chantelau E, Spraul M, Muhlhauser I, et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia. 1989;32(7):421–426.
   PubMed Web of Science ®Google Scholar
• Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(5):573–576.
   PubMed Web of Science ®Google Scholar
• Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care. 1988;11(1):46–51.
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17(6):1235–1241.
   PubMed Web of Science ®Google Scholar
• Sesar Á, Fernández-Pajarín G, Ares B, et al. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946–954.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, De Pandis MF, et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci. 2001;22(1):93–94.
   PubMed Web of Science ®Google Scholar
• Tyne HL, Parsons J, Sinnott A, et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol. 2004;251(11):1370–1374.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766–768.
   PubMed Web of Science ®Google Scholar
• Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidem Drug Safe. 1992;1(6):347–349.
   Google Scholar
• Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy. 2003;23(5):686–689.
   PubMed Web of Science ®Google Scholar
• National Health Service [NHS] Digital. Read codes [Internet]. [cited 2020 Sep 25]. Available from: https://digital.nhs.uk/services/terminology-and-classifications/read-codes
   Google Scholar
• Electronic Medicines Compendium. APO-go PFS 5mg/ml solution for infusion in pre-filled syringe [Internet]. [cited 2020 Oct 20]. Available from: https://www.medicines.org.uk/emc/product/3908/
   Google Scholar
• Electronic Medicines Compendium. NovoRapid PumpCart 100 units/ml [Internet]. [cited 2020 Oct 20]. Available from: https://www.medicines.org.uk/emc/product/7922
   Google Scholar